CDK4 Inhibitors Thwart Immunity by Inhibiting Phospho-RB-NF-κB Complexes.

Seung J Kim, Samuel Asfaha, Frederick A Dick

Abstract readComment

In one paragraph

Article in Molecular cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it

0cells of the map it votes in

7citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity.Cancers · 2025
Review
Alternate actions of CDK4/6 inhibitors beyond cell cycle blockade: unexplored roles in therapy resistance.Cancer metastasis reviews · 2025
Review
CDK4/6 inhibitors upregulate cIAP1/2, and Smac mimetic LCL161 enhances their antitumor effects in cholangiocarcinoma cells.Scientific reports · 2025
Article
Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy.Cellular and molecular life sciences : CMLS · 2024
Review
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy.Nature communications · 2023
Article
The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer.Frontiers in cell and developmental biology · 2021
Article
NF-κB and Its Role in Checkpoint Control.International journal of molecular sciences · 2020
Review

4 · The record

Corrections and comments

Comment on
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.2019

5 · Who and what money

Authors and funding

3 authors.

Seung J KimLondon Regional Cancer Program, London, ON, Canada; Children's Health Research Institute, London, ON, Canada; Department of Biochemistry, Western University, London, ON, Canada.

Samuel AsfahaLondon Regional Cancer Program, London, ON, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada; Department of Medicine, Western University, London, ON, Canada.

Frederick A DickLondon Regional Cancer Program, London, ON, Canada; Children's Health Research Institute, London, ON, Canada; Department of Biochemistry, Western University, London, ON, Canada. Electronic address: fdick@uwo.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PD-L1 plays a central role in immune recognition of cancer cells. In this issue of Molecular Cell, Jin et al. (2019) report that a phosphorylated retinoblastoma protein contacts the DNA-binding domain of p65 NF-κB, thereby blocking transcription of PD-L1.

Indexed as

B7-H1 AntigenGene Expression RegulationNF-kappa BRetinoblastoma ProteinSignal TransductionTranscription Factor RelAB7-H1 AntigenNF-kappa BRetinoblastoma ProteinTranscription Factor RelA

Identifiers

PMID30609388

DOI10.1016/j.molcel.2018.12.012

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.